Developing a novel class of cancer therapies called RIPTACTM (Regulated Induced Proximity Targeting Chimeras) therapeutics
Location: United States, Connecticut, New Haven
Total raised: $126M
Investors 3
| Date | Name | Website |
| - | Connecticu... | ctinnovati... |
| 16.09.2024 | Vida Ventu... | vidaventur... |
| - | Access Bio... | accessbio-... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.08.2024 | Series B | $126M | - |
Mentions in press and media 8
| Date | Title | Description |
| 24.02.2025 | Halda Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating HLD-0915 in Metastatic Castration-Resistant Prostate Cancer | - |
| 01.10.2024 | Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer | - |
| 14.08.2024 | Halda Therapeutics: A New Dawn in Cancer Treatment | In the relentless battle against cancer, drug resistance often feels like a formidable fortress. Standard treatments, while effective for many, frequently fall short as tumors evolve and adapt. This is where Halda Therapeutics enters the fr... |
| 12.08.2024 | Halda Therapeutics Secures $126 Million Financing to Advance RIPTAC™ Cancer Therapies into the Clinic for Major Solid Tumors | - |
| 12.08.2024 | Halda Therapeutics raises $126M to overcome drug resistance in cancer | The company will start clinical trials for prostate cancer, and develop a breast cancer therapeutic Drug resistance to standard treatments is common in metastatic cancer: some reasons for this include tumor heterogeneity where cancer cells ... |
| 12.08.2024 | Halda raises $126M to advance 'hold and kill' solid tumor drugs into the clinic | The initial stages of oncology R&D aren’t short of intriguing new modalities, and Halda Therapeutics is planning to join them by using $126 million in fresh funding to bring its RIPTAC program into the clinic. RIPTAC—which stands for Re... |
| 12.08.2024 | Halda Therapeutics Raises $126M in Series B Extension Financing | Halda Therapeutics, a New Haven, CT-based biotechnology company developing a novel class of cancer therapies called RIPTACTM (Regulated Induced Proximity TArgeting Chimeras) therapeutics, raised $126M in Series B extension funding. The roun... |
| - | Halda Therapeutics | “Halda is developing RIPTAC™ therapeutics, a new class of precision medicines to defeat cancer.” |